[Laboratory and clinical studies on cefroxadine (author's transl)]

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Cefroxadine (CXD) is an antibiotic used for pediatric infections.
• Understanding its pharmacokinetic and pharmacodynamic properties is crucial for effective treatment.

Purpose of the Study:

• To evaluate the serum concentration, urinary excretion, antibacterial activity, and clinical efficacy of Cefroxadine in children.
• To assess the safety profile of Cefroxadine in pediatric patients.

Main Methods:

• Pharmacokinetic analysis involved oral administration of CXD dry syrup (10 mg/kg) and measurement of serum concentrations and urinary excretion.
• Antibacterial activity was determined by Minimum Inhibitory Concentration (MIC) assays against various bacterial pathogens.
• A clinical study treated 37 children with bacterial infections using CXD dry syrup (approx. 48 mg/kg/day in 3 divided doses).

Main Results:

• Peak serum concentrations of CXD averaged 16.41 µg/ml within 1-2 hours post-administration.
• Average urinary excretion rate was 93.9% within 6 hours.
• CXD exhibited comparable or slightly superior Minimum Inhibitory Concentrations (MICs) to CEX against tested bacteria.
• An overall efficacy rate of 91.7% was observed in 37 pediatric patients with various bacterial infections, with no significant side effects reported.

Conclusions:

• Cefroxadine is well-absorbed and rapidly excreted in children, indicating favorable pharmacokinetics.
• CXD possesses significant antibacterial activity and demonstrates high clinical efficacy and safety in treating pediatric bacterial infections.